Study guide
10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
Key Takeaways Explain This Topic AI
Retail community pharmacies are strictly prohibited from possessing, receiving, or storing prescription drug samples under any circumstances under the PDMA.
Prescription drug samples may only be distributed to licensed prescribers or hospital/health-system pharmacies pursuant to a signed written request from a licensed practitioner.
Reimportation of U.S.-manufactured prescription drugs (American Goods Returned) is illegal except when reimported directly by the original manufacturer.
Starter packs (trial packs) are commercial stock packages intended to initiate therapy; retail pharmacies are legally permitted to possess starter packs.
Wholesale drug distributors must be state-licensed and accredited (e.g., NABP Drug Distributor Accreditation / VAWD) to prevent drug diversion and secondary grey-market resales.
Last updated: November 2026
10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
MPJE Core Concept: The Prescription Drug Marketing Act (PDMA) of 1987 (enacted as an amendment to the Federal Food, Drug, and Cosmetic Act) regulates the commercial distribution of prescription drugs to prevent drug diversion, adulteration, and counterfeiting. Key MPJE topics include the strict prohibition against retail pharmacies possessing drug samples , strict requirements for hospital sample distribution , the federal reimportation ban , and wholesale distributor licensing .
Legislative Intent and Overview of PDMA
Congress passed the PDMA in 1987 in response to widespread evidence of a "secondary wholesale market" operating without adequate oversight. Unscrupulous entities were buying discounted institutional drugs, expired samples, and diverted products, repackaging them, and re-entering them into the commercial retail drug supply.
Core Objectives of the PDMA
Ban the Sale of Drug Samples: Eliminate commercial trade, sale, purchase, or offer to sell prescription drug samples.
Restrict Sample Possession: Completely prohibit retail community pharmacies from possessing prescription drug samples.
Control Reimportation: Ban the reimportation of U.S.-manufactured prescription drugs (American Goods Returned) except by the original manufacturer.
License Wholesalers: Establish state licensing standards for wholesale prescription drug distributors.
Restrict Resale by Healthcare Entities: Prohibit hospitals and health care entities from reselling drug purchases to retail pharmacies.
Prescription Drug Samples: Strict Federal Controls
A prescription drug sample is defined under the PDMA as a unit of a prescription drug that is not intended to be sold and is intended to promote the sale of the drug. +-----------------------------------------------------------------------------+
- | RETAIL PHARMACY SAMPLE PROHIBITION |
- | |
- | RETAIL COMMUNITY PHARMACIES ARE STRICTLY PROHIBITED FROM POSSESSING, |
- | RECEIVING, OR STORING PRESCRIPTION DRUG SAMPLES UNDER ANY CIRCUMSTANCES. |
- | |
- | * Possession of even a single sample in a retail pharmacy is a violation |
- | of federal law (FD&C Act / PDMA) and constitutes misbranding. |
- +-----------------------------------------------------------------------------+
- Institutional & Hospital Pharmacy Sample Rules
While retail community pharmacies can never possess drug samples, institutional health-system pharmacies (e.g., hospital pharmacies) and licensed prescribers may receive and store drug samples under strict statutory conditions:
Written Request Required: Drug samples may only be distributed by a manufacturer or authorized distributor to a licensed practitioner (prescriber) or to a hospital/health care entity pharmacy pursuant to a written request signed by the licensed practitioner.
Written Request Elements: The written request must contain:
Name, address, professional title, and license number of the practitioner.
Name, strength, dosage form, and quantity of the sample requested.
Name of the manufacturer/distributor.
Date of the request and signature of the practitioner.
Standing Written Requests: Requests must be executed annually or per shipment; standing oral requests are illegal.
Receipt & Inventory Records: The institutional pharmacy must maintain receipt records, store samples separate from commercial inventory, and conduct annual physical inventories.
Starter Packs vs. Prescription Drug Samples
On the MPJE, candidates must distinguish between prescription drug samples and starter packs :
Feature Prescription Drug Sample Starter Pack / Trial Pack
Definition Free unit intended solely to promote sales; not to be sold Initial stock package provided free or at low cost to retail pharmacies to start patient therapy
Retail Pharmacy Possession STRICTLY PROHIBITED PERMITTED
Billing / Sale Cannot be sold or billed to patient/insurance Distributed to patient pursuant to Rx; may charge dispensing fee if allowed
- Labeling Marked "Sample - Not for Sale" Standard commercial package labeling & NDC
- Reimportation Restrictions (American Goods Returned)
The PDMA generally prohibits the reimportation of U.S.-manufactured prescription drugs that have been exported to foreign countries. This rule is often referred to as the "American Goods Returned" provision .
General Rule & Manufacturer Exception
General Prohibition: No prescription drug manufactured in the United States that was exported may be reimported back into the U.S. by anyone other than the original manufacturer .
Rationale: Once a drug leaves the regulated U.S. supply chain, the FDA cannot guarantee its storage conditions, temperature control, authenticity, or safety.
Personal Importation & Compassionate Use (FDA Guidance)
Under strict FDA enforcement discretion, individuals may personally import small quantities of unapproved foreign drugs for personal use under the Compassionate Use Exemption , provided ALL of the following criteria are met:
The drug is for a serious condition for which effective treatment is not available domestically.
There is no commercialization or promotion of the drug to U.S. residents.
The drug does not represent an unreasonable health risk.
The individual provides the name and address of the licensed U.S. physician treating them.
The quantity imported does not exceed a 90-day supply .
Wholesale Distributor Licensing & Resale Restrictions
The PDMA prohibits hospitals, health systems, and charitable health care entities from reselling or transferring prescription drugs to retail community pharmacies. This prevents arbitrage where non-profit institutions buy drugs at steep preferential discounts and flip them to retail entities for profit.
Exceptions to Hospital Resale Prohibition
Intracompany Sales: Transfers between hospitals or healthcare entities under common control.
Emergency Medical Reasons: Emergency transfers to a retail pharmacy or distributor to alleviate a temporary localized shortage.
Group Purchasing Organizations (GPOs): Purchases made through a GPO for the institution's own use.
Outpatient Dispensing: Dispensing drugs pursuant to prescriptions to hospital employees, retirees, or bona fide outpatient clinic patients.
Wholesale Licensing & NABP Accreditation (VAWD)
State Licensing: All wholesale distributors must be licensed by the state in which they reside and every state into which they ship prescription drugs.
NABP Drug Distributor Accreditation: Formerly known as VAWD (Verified-Accredited Wholesale Distributors) , this accreditation verifies that wholesale facilities meet rigorous facility security, background check, storage control, and DSCSA compliance standards.
Comparative Matrix: PDMA vs. DSCSA Standards
Regulatory Area PDMA Requirement (1987) DSCSA Requirement (2013+)
Primary Focus Drug sample controls, reimportation ban, state wholesale licensing Electronic package-level track-and-trace, product identifiers
Pedigree System Required paper pedigrees for non-authorized wholesalers Replaced paper pedigrees with interoperable electronic product tracing ( TI and TS ; the TH requirement ended November 27, 2023)
Sample Storage Strictly prohibited in retail pharmacies; allowed in hospitals via written Rx request Maintains PDMA sample rules without modification